Fosaprepitant Weekly vs Every 3 Weeks for the Prevention of Concurrent Chemoradiotherapy–Induced Nausea and Vomiting: A Pilot Randomized Clinical Trial

IMPORTANCE: Unlike substantial evidence in the prevention of chemotherapy-induced nausea and vomiting (CINV), research in the prevention of nausea and vomiting caused by concurrent chemoradiotherapy (CCRT) is currently lacking. OBJECTIVE: To compare the efficacy and safety of fosaprepitant weekly vs...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Qi, Zou, Xiong, Xie, Yu-Long, Lin, Chao, Ouyang, Yan-Feng, Liu, Yong-Long, Duan, Chong-Yang, You, Rui, Liu, You-Ping, Liu, Rong-Zeng, Huang, Pei-Yu, Guo, Ling, Hua, Yi-Jun, Chen, Ming-Yuan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2023
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10375310/
https://www.ncbi.nlm.nih.gov/pubmed/37498596
http://dx.doi.org/10.1001/jamanetworkopen.2023.26127

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10375310/
https://www.ncbi.nlm.nih.gov/pubmed/37498596
http://dx.doi.org/10.1001/jamanetworkopen.2023.26127

Ejemplares similares